4.4 Article

Impact of Multidrug Resistance on Experimental Empyema by Pseudomonas aeruginosa

Journal

RESPIRATION
Volume 82, Issue 1, Pages 46-53

Publisher

KARGER
DOI: 10.1159/000326893

Keywords

Empyema; Multidrug resistance; Pseudomonas aeruginosa; Apoptosis

Ask authors/readers for more resources

Background: Pseudomonas aeruginosa is a cause of infections of the lower respiratory tract among patients with chronic lung disorders. It is questionable whether virulence of this species may be influenced by multidrug resistance (MDR). Objectives: To define the impact of MDR in experimental lung infection. Methods: Experimental empyema was induced in rabbits by MDR (group A, n = 16) and by susceptible isolates (group B, n = 10). Pleural fluid was sampled for quantitative culture and estimation of cell apoptosis and of tumor necrosis factor-alpha (TNF alpha) and malondialdehyde (MDA). Survival was recorded. Cytokine production was stimulated in U937 monocytes by samples of pleural fluid. Whole blood of rabbits was incubated with the isolates; induction of apoptosis was assessed. Results: Survival of group A was prolonged compared to group B. This was accompanied by lower bacterial counts of the inoculated pathogens in pleural fluid and in the lungs of group A compared with group B. Early apoptosis of neutrophils of pleural fluid of group A was lower compared with group B. Pleural fluid concentrations of TNF alpha and MDA did not differ between the groups. Cytokine production by U937 monocytes after stimulation with pleural fluid was greater in group B than in group A. The susceptible isolate induced apoptosis of neutrophils in vitro at a greater rate than the MDR isolate. Conclusions: Experimental empyema by susceptible P. aeruginosa is accompanied by greater mortality compared with MDR P. aeruginosa. This phenomenon may be attributed to the different growth pattern of the pathogens or to their interaction with the innate immune system. Copyright (C) 2011 S. Karger AG, Basel

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

Calprotectin and Imbalances between Acute-Phase Mediators Are Associated with Critical Illness in COVID-19

Georgios Kassianidis, Athanasios Siampanos, Garyphalia Poulakou, George Adamis, Aggeliki Rapti, Haralampos Milionis, George N. Dalekos, Vasileios Petrakis, Styliani Sympardi, Symeon Metallidis, Zoi Alexiou, Theologia Gkavogianni, Evangelos J. Giamarellos-Bourboulis, Theoharis C. Theoharides

Summary: This study investigates the trajectory of moderate and severe COVID-19 progressing to ARDS requiring MV. The levels of various mediators were analyzed in patients at different stages of severity. The study found that levels of proinflammatory mediators were increased in patients with ARDS and MV, while levels of anti-inflammatory mediators also showed an increase. Pathways involving IL-6, IL-33, and calprotectin were significantly associated with worse outcomes. Further research is needed to understand the importance of these findings in relation to other acute-phase reactants.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Editorial Material Dermatology

Keratinocytes as drivers of hidradenitis suppurativa inflammation: need for priming

Evangelos J. Giamarellos-Bourboulis

BRITISH JOURNAL OF DERMATOLOGY (2023)

Review Microbiology

Probiotics in Functional Dyspepsia

Georgios Tziatzios, Paraskevas Gkolfakis, Gabriela Leite, Ruchi Mathur, Georgia Damoraki, Evangelos J. J. Giamarellos-Bourboulis, Konstantinos Triantafyllou

Summary: Functional dyspepsia (FD) is a common disorder with no definitive, universal treatment. Probiotics have been suggested as a potential therapeutic option for FD due to their effects on gastrointestinal symptoms in patients with Irritable Bowel Syndrome (IBS). However, the evidence for the efficacy of probiotics in FD remains unclear. This review aims to summarize the available evidence for the use of probiotics in FD.

MICROORGANISMS (2023)

Article Hematology

An active new formulation of iron carried by aspartyl casein for iron-deficiency anemia: results of the ACCESS trial

Maria Tsilika, John Mitrou, Nikolaos Antonakos, Ioulia K. Tseti, Georgia Damoraki, Konstantinos Leventogiannis, Evangelos J. Giamarellos-Bourboulis

Summary: The clinical trial of the new oral iron formulation, Fe-ASP, demonstrates its non-inferiority to ferrous sulfate in increasing hemoglobin levels and improving global score and reducing iron-deficiency anemia-related physical signs.

ANNALS OF HEMATOLOGY (2023)

Article Infectious Diseases

REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI

Theodossis Papavramidis, Ivan Gentile, Anna Maria Cattelan, Laura Magnasco, Pierluigi Viale, Daniela Francisci, Diamantis P. Kofteridis, Giusy Tiseo, Evangelos J. Giamarellos-Bourboulis, Filippo Lagi, Simone Mornese Pinna, Federico D'Amico, Lucia La Ferla, Periklis Panagopoulos, Gianni Gattuso, Nikolaos V. Sipsas, Alessandro Ruggieri, Agnese Cattaneo, Luciana Corio, Alessandro Comandini, Patrizia Mascagni, Matteo Bassetti

Summary: A multicentre, observational, retrospective study showed that dalbavancin can significantly reduce hospital stay, decrease healthcare costs, and improve treatment efficacy and safety for patients with acute bacterial skin and skin-structure infections.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2023)

Article Biochemistry & Molecular Biology

Evaluation of the Novel Sepsis Biomarker Host-Derived Delta-like Canonical Notch Ligand 1-A Secondary Analysis of 405 Patients Suffering from Inflammatory or Infectious Diseases

Tobias Hoelle, Patrick Rehn, Konstantinos Leventogiannis, Antigone Kotsaki, Theodora Kanni, Nikolaos Antonakos, Christos Psarrakis, Georgia Damoraki, Judith Schenz, Felix C. F. Schmitt, Florian Uhle, Markus A. Weigand, Evangelos J. Giamarellos-Bourboulis, Maximilian Dietrich

Summary: This study evaluated the potential of Host-Derived Delta-like Canonical Notch Ligand 1 (DLL1) as a biomarker for diagnosing sepsis. Results showed that plasma levels of soluble DLL1 were significantly elevated in patients with sepsis compared to those with uncomplicated infections and sterile inflammation. DLL1 demonstrated better diagnostic performance for sepsis compared to other biomarkers such as C-reactive protein, procalcitonin, and White Blood Cell count.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Letter Dermatology

Immune Classification of Hidradenitis Suppurativa: Modulation by Secukinumab

Dimitra Stergianou, Styliani Micha, Vassiliki Tzanetakou, Theodora Kanni, Theologia Gkavogianni, Alexandros Katoulis, Evangelos J. Giamarellos-Bourboulis

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2023)

Article Multidisciplinary Sciences

Anakinra in hospitalized COVID-19 patients guided by baseline soluble urokinase plasminogen receptor plasma levels: A real world, retrospective cohort study

Francesco Vladimiro Segala, Emanuele Rando, Federica J. Salvati, Marcantonio Negri, Francesca Catania, Flavia Sanmartin, Rita Murri, Evangelos Giamarellos-Bourboulis, Massimo Fantoni

Summary: A retrospective cohort study found that early administration of anakinra, an interleukin-1 receptor antagonist, guided by baseline suPAR levels, can prevent disease progression and death in COVID-19 patients. In the absence of suPAR testing, the SCOPE score can be used as an alternative for treatment decisions.

PLOS ONE (2023)

Article Health Care Sciences & Services

Modified SCOPE (mSCOPE) Score as a Tool to Predict Mortality in COVID-19 Critically Ill Patients

Stavroula Zanelli, Agamemnon Bakakos, Zoi Sotiropoulou, Andriana I. Papaioannou, Evangelia Koukaki, Efstathia Potamianou, Anna Kyriakoudi, Evangelos Kaniaris, Petros Bakakos, Evangelos J. Giamarellos-Bourboulis, Antonia Koutsoukou, Nikoletta Rovina

Summary: This study assessed the modified Severe COvid Prediction Estimate score (mSCOPE) as a predictor of mortality in ICU-admitted severe COVID-19 pneumonia patients. The results showed that patients with higher mSCOPE scores had a higher mortality rate and were correlated with disease severity, comorbidity severity, days on mechanical ventilation, and days of ICU stay. The mSCOPE score can be a useful tool for risk stratification in patients with severe COVID-19.

JOURNAL OF PERSONALIZED MEDICINE (2023)

Editorial Material Dermatology

Interleukin-17A derived from mast cells: evidence for an autoinflammatory loop in hidradenitis suppurativa?

Evangelos J. Giamarellos-Bourboulis

BRITISH JOURNAL OF DERMATOLOGY (2023)

Article Pathology

Biomarkers to guide immunomodulatory treatment: where do we stand?

Evdoxia Kyriazopoulou, Evangelos J. Giamarellos-Bourboulis, Karolina Akinosoglou

Summary: This review summarizes the current progress in the development of biomarkers to guide immunotherapy in oncology, rheumatology, and critical illness.

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2023)

Correction Critical Care Medicine

Sepsis, a call for inclusion in the work plan of the European Center for Disease Prevention and Control (vol 49, pg 1138, 2023)

Evangelos J. Giamarellos-Bourboulis, Annelies S. Zinkernagel, Edoardo De Robertis, Elie Azoulay, Daniele De Luca

INTENSIVE CARE MEDICINE (2023)

Letter Critical Care Medicine

Sepsis, a call for inclusion in the work plan of the European Center for Disease Prevention and Control

Evangelos J. Giamarellos-Bourboulis, Annelies S. Zinkernagel, Edoardo De Robertis, Elie Azoulay, Daniele De Luca

INTENSIVE CARE MEDICINE (2023)

Article Cardiac & Cardiovascular Systems

Analysis of inflammatory protein profiles in the circulation of COVID-19 patients identifies patients with severe disease phenotypes

Nick Keur, Maria Saridaki, Isis Ricano-Ponce, Mihai G. Netea, Evangelos J. Giamarellos-Bourboulis, Vinod Kumar

Summary: This study identified protein biomarkers associated with COVID-19 severity through the measurement of plasma protein levels. It also identified three clinical endotypes of the disease. These findings suggest that circulating proteins may be useful for predicting COVID-19 outcomes and may be applicable to other populations.

RESPIRATORY MEDICINE (2023)

Article Multidisciplinary Sciences

A randomized clinical trial of bermekimab treatment for clinical improvement of systemic sclerosis

Nicky Solomonidi, Panayiotis G. Vlachoyiannopoulos, Maria Pappa, Georgia Liantinioti, Sofia Ktena, Evangelos Theotikos, Antonia Elezoglou, Mihai G. Netea, Evangelos J. Giamarellos-Bourboulis

Summary: This study found that increased concentrations of IL-1 alpha are present in SSc patients. Treatment with the IL-1 alpha blocking antibody, bermekimab, effectively inhibits disease progression and reduces inflammation.

ISCIENCE (2023)

No Data Available